HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

EMA Approval Sought for Neratinib in HER2+ Breast Cancer

June 28th 2016

A marketing authorization application has been submitted to the European Medicines Agency for neratinib as a potential extended adjuvant therapy for patients with HER2-positive early stage breast cancer following 12 months of trastuzumab.

Final Thoughts on Advanced Breast Cancer

June 23rd 2016

Practice-Changing Results from the MINDACT Trial

June 23rd 2016

AC versus TaxAC in High-Risk HER2-Negative MBC

June 23rd 2016

Adjuvant Therapy for Breast Cancer

June 23rd 2016

Immunotherapy for TNBC

June 23rd 2016

Is There a Role for TNBC Subtyping?

June 23rd 2016

Biosimilar Trastuzumab in HER2-Positive Breast Cancer

June 23rd 2016

Neratinib and HER2 Activating Mutations in Breast Cancer

June 23rd 2016

Patient Selection for Neratinib in Metastatic Breast Cancer

June 23rd 2016

The Emerging Role of Neratinib in HER2+ MBC

June 23rd 2016

PHEREXA Trial in HER2+ Disease

June 23rd 2016

Adjuvant TDM-1 and the KRISTINE Trial

June 23rd 2016

What is New for HER2 MBC?

June 23rd 2016

The Emerging Role of PI3K Inhibition in Breast Cancer

June 23rd 2016

The Ongoing Role of Everolimus in ER-Positive MBC

June 23rd 2016

FDA Breakthrough Status for Abemaciclib

June 23rd 2016

CDK4/6 Inhibitors in Hormone Receptor-Driven MBC

June 23rd 2016

ESR Mutations and Resistance to Endocrine Therapy in Breast Cancer

June 23rd 2016

Burris Discusses T-DM1 Update, Neoadjuvant Care in HER2+ Breast Cancer

June 23rd 2016

Howard A. "Skip" Burris, MD, offers insight on patient-reported outcomes from the MARIANNE trial and highlights exciting advancements in the neoadjuvant landscape of HER2-positive breast cancer.

x